Effect of exenatide on the cardiac expression of adiponectin receptor 1 and NADPH oxidase subunits and heart function in streptozotocin-induced diabetic rats

BackgroundThis study investigated the effect of exenatide on the cardiac expression of adiponectin receptor 1 and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase subunits and heart function in streptozotocin-induced diabetic rats.MethodsMale Sprague–Dawley rats were randomly divided into four groups, i.e. control group, diabetic group, diabetic treated with low doses of exenatide (2 μg · kg−1.d−1) and diabetic treated with high doses of exenatide (10 μg · kg−1.d−1). Diabetes was induced by intraperitoneal injection of streptozotocin (65 mg/kg body weight). At the termination after exenatide treatment for eight weeks, following anesthesia of the rats, a catheter was inserted into the left ventricle through the right common carotid artery for measurement of left ventricular pressure, which included left ventricular systolic pressure (LVSP), left ventricular end-diastolic pressure (LVEDP) and the maximal rate of rise and decline of ventricular pressure (±dp/dt[max]). Plasma and myocardial adiponectin levels, and the expressions of myocardial adiponectin receptor 1, p22phox, NADPH oxidase 4 (NOX4), glucose transporter type 4 (Glut4), AMPK-α, phosphorylated-AMPK-α, connective tissue growth factor (CTGF) and copper zinc superoxide dismutase (Cu-Zn-SOD) were assayed.ResultsHeart function, plasma adiponectin levels, the protein expression of myocardial phosphorylated-AMPK-α, the mRNA expression of myocardial Glut4, and the positive expression of myocardial Cu-Zn-SOD were significantly decreased in diabetic. The protein expression of myocardial adiponectin receptor 1, the mRNA expression of myocardial p22phox and NOX4, and the positive expression of myocardial CTGF were significantly increased in diabetic. Low and high doses of exenatide treatment significantly attenuated these changes in diabetic rats.ConclusionsThese results suggest that exenatide may contribute to the improvement of the heart function in diabetic rats by down-regulating the expression of myocardial adiponectin receptor 1, p22phox and NOX4, and up-regulating plasma adiponectin level and the expression of myocardial AMPK-α, Glut4 and Cu-Zn-SOD.

• Publication year

  2014

• Venue

  Diabetology & Metabolic Syndrome

• Publication date

  2014-02-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/1758-5996-6-29PMID 24576329PMCID 3942060
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Glucagon-Like Peptide-1 Protects Against Cardiac Microvascular Injury in Diabetes via a cAMP/PKA/Rho-Dependent Mechanism

  2013cited by this paper
• Dipeptidyl peptidase IV inhibition upregulates GLUT4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats.

  2013cited by this paper
• Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes.

  2013cited by this paper
• GLP-1 and cardioprotection: from bench to bedside.

  2012cited by this paper
• Glucagon-Like Peptide-1 and its Cardiovascular Effects

  2012cited by this paper
• Cardiovascular biology of the incretin system.

  2012cited by this paper
• Effect of rosiglitazone on the expression of cardiac adiponectin receptors and NADPH oxidase in type 2 diabetic rats.

  2012cited by this paper
• The effect of glucagon-like peptide 1 on cardiovascular risk

  2012cited by this paper
• Effect of telmisartan on the expression of cardiac adiponectin and its receptor 1 in type 2 diabetic rats

  2011cited by this paper
• Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes

  2011cited by this paper
• Sudeck's disease stage 1, or diabetic Charcot's foot stage 0? Case report and assessment of the diagnostic value of MRI

  2010cited by this paper
• Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury.

  2009cited by this paper
• Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression.

  2009cited by this paper
• Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

  2008cited by this paper
• Signalling pathways activated by glucagon-like peptide-1 (7-36) amide in the rat heart and their role in protection against ischaemia

  2008cited by this paper
• Chronic Glucagon-Like Peptide-1 Infusion Sustains Left Ventricular Systolic Function and Prolongs Survival in the Spontaneously Hypertensive, Heart Failure–Prone Rat

  2008cited by this paper
• Downregulation of NADPH oxidase, antioxidant enzymes, and inflammatory markers in the heart of streptozotocin-induced diabetic rats by N-acetyl-L-cysteine.

  2007cited by this paper
• Biology of incretins: GLP-1 and GIP.

  2007cited by this paper
• Cardiac expression of adiponectin and its receptors in streptozotocin-induced diabetic rats.

  2007cited by this paper
• Redox signalling involving NADPH oxidase-derived reactive oxygen species.

  2006cited by this paper
• Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.

  2006cited by this paper
• AMPK alterations in cardiac physiology and pathology: enemy or ally?

  2006cited by this paper
• Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism.

  2005cited by this paper
• Adiponectin is synthesized and secreted by human and murine cardiomyocytes

  2005cited by this paper
• Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.

  2005cited by this paper
• corrigendum: Cloning of adiponectin receptors that mediate antidiabetic metabolic effects

  2004cited by this paper
• Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion

  2004cited by this paper
• Recombinant Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake and Improves Left Ventricular Performance in Conscious Dogs With Pacing-Induced Dilated Cardiomyopathy

  2004cited by this paper
• The effects of iron dextran on the oxidative stress in cardiovascular tissues of rats with chronic renal failure.

  2004cited by this paper
• Cloning of adiponectin receptors that mediate antidiabetic metabolic effects

  2003cited by this paper
• Cardiac function in mice lacking the glucagon-like peptide-1 receptor.

  2003cited by this paper
• Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase

  2002cited by this paper
• Activation of NADPH Oxidase During Progression of Cardiac Hypertrophy to Failure

  2002cited by this paper
• Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

  2001cited by this paper
• NAD(P)H oxidase: role in cardiovascular biology and disease.

  2000cited by this paper
• Role of oxygen derived radicals for vascular dysfunction in the diabetic heart: Prevention by α-tocopherol?

  1998cited by this paper
• Economic Consequences of Diabetes Mellitus in the U.S. in 1997

  1998cited by this paper
• Diabetes mellitus, hypertension, and cardiovascular disease: which role for oxidative stress?

  1995cited by this paper
• Tissue‐specific expression of the human receptor for glucagon‐like peptide‐I: brain, heart and pancreatic forms have the same deduced amino acid sequences

  1995cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• O R I G I N a L I N V E S T I G a T I O N Open Access

  year unknowncited by this paper

• Anti-Inflammatory and Anti-Oxidative Effects of GLP1-RAs and SGLT2i: The Guiding Star Towards Cardiovascular Protection in Type 2 Diabetes

  2025cites this paper
• Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential

  2025cites this paper
• Diabetic Cardiomyopathy: What Clinicians Should Know.

  2024cites this paper
• GLP-1 RAs and SGLT2i: two antidiabetic agents associated with immune and inflammation modulatory properties through the common AMPK pathway

  2023cites this paper
• The comparison of the antidiabetic effects of exenatide, empagliflozin, quercetin, and combination of the drugs in type 2 diabetic rats

  2023cites this paper
• Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases.

  2022cites this paper
• Role of AMPK in Myocardial Ischemia-Reperfusion Injury-Induced Cell Death in the Presence and Absence of Diabetes

  2022cites this paper
• Therapeutic potential of targeting oxidative stress in diabetic cardiomyopathy.

  2021cites this paper
• NADPH Oxidase 2 Mediates Myocardial Oxygen Wasting in Obesity

  2020cites this paper
• Exendin‐4 protects the hearts of rats from ischaemia/reperfusion injury by boosting antioxidant levels and inhibition of JNK/p66Shc/NADPH axis

  2020cites this paper
• AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases

  2019cites this paper
• The effect of exenatide (a GLP‐1 analog) and sitagliptin (a DPP‐4 inhibitor) on plasma platelet‐activating factor acetylhydrolase (PAF‐AH) activity and concentration in normal and fructose‐fed rats

  2019cites this paper
• The role of NADPH oxidases in diabetic cardiomyopathy.

  2017cites this paper
• Adipocyte-Specific Deficiency of NADPH Oxidase 4 Delays the Onset of Insulin Resistance and Attenuates Adipose Tissue Inflammation in Obesity

  2017cites this paper
• Combination treatment of adipose-derived stem cells and adiponectin attenuates pulmonary arterial hypertension in rats by inhibiting pulmonary arterial smooth muscle cell proliferation and regulating the AMPK/BMP/Smad pathway

  2017cites this paper
• Exogenous hydrogen sulphide ameliorates diabetic cardiomyopathy in rats by reversing disordered calcium‐handling system in sarcoplasmic reticulum

  2016cites this paper
• Characteristics, causes and functional consequences of brain inflammation in diabetes and hypertension

  2015cites this paper
• Upregulation of arginase activity contributes to intracellular ROS production induced by high glucose in H9c2 cells.

  2015cites this paper
• Interplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy.

  2015cites this paper
• Cardiovascular function in rat models of diabetes – the roles of hyperglycemia, inflammation and oxidative stress

  2015cites this paper